Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non–Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co‐primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate...

Descripción completa

Detalles Bibliográficos
Autores principales: de Castro, Gilberto, Kudaba, Iveta, Wu, Yi-Long, Lopes, Gilberto, Kowalski, Dariusz M., Turna, Hande Z., Caglevic, Christian, Zhang, Li, Karaszewska, Boguslawa, Laktionov, Konstantin K., Srimuninnimit, Vichien, Bondarenko, Igor, Kubota, Kaoru, Mukherjee, Rinee, Lin, Jianxin, Souza, Fabricio, Mok, Tony S.K., Cho, Byoung Chul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2023
Materias:
CLINICAL TRIAL UPDATES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10082298/
https://www.ncbi.nlm.nih.gov/pubmed/36306479
http://dx.doi.org/10.1200/JCO.21.02885

Ejemplares similares

Ejemplares similares